“This event-driven study remains on track to read out in 2027.”

In context

“top and bottom line guidance. David will provide more detail shortly. We continue to advance our pipeline during the quarter, with several recent announcements. Opdivo plus Yervoy received FDA and EMA approvals for the treatment of first-line liver cancer and FDA approval for use in MSI high colorectal cancer in the US, further solidifying its leadership in immuno-oncology. Breyanzi was approved in the EU for treatment of follicular lymphoma, expanding our cell therapy presence in blood cancers. Camzyos received approval in Japan and a favorable label update in the US, which reduces the REMS echo monitoring requirement in the maintenance phase. In addition, Milvexian reached an important milestone in the quarter with the completion of enrollment in the Librexia atrial fibrillation trial. This event-driven study remains on track to read out in 2027. Turning to slide five and our two recent top-line readouts, while we're disappointed that the Camzyos Odyssey study in non-obstructive HCM and the Cobenfi Arise study in adjunctive schizophrenia did not meet their primary endpoints, I want to put the results in proper context. Although these are not the results that we had hoped for, neither outcome meaningfully alters our strategy or growth trajectory. For Camzyos, the study strongly suggests that non-obstructive and obstructive HCM behave distinctly. We do not expect these data to significantly impact peak sales, and our focus remains on our existing obstructive HCM indication, which represents the vast majority of the market opportunity. For Cobenfi, although it did not demonstrate a statistically significant improvement as an adjuncti”